ReShape Lifesciences (RSLS)
NASDAQ:RSLS
Holding RSLS?
Track your performance easily

ReShape Lifesciences (RSLS) Financial Statements

464 Followers

ReShape Lifesciences Financial Overview

ReShape Lifesciences's market cap is currently ―. The company's EPS TTM is $-72.655; its P/E ratio is -0.08; ReShape Lifesciences is scheduled to report earnings on November 7, 2024, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
Jun 24Mar 24Dec 23Sep 23Jun 23
Income Statement-
Total Revenue$ 1.97M$ 1.94M$ 1.98M$ 2.15M$ 2.25M
Gross Profit$ 1.13M$ 1.17M$ 1.84M$ 1.29M$ 1.19M
EBIT$ -1.58M$ -2.18M$ -1.90M$ -3.53M$ -3.49M
EBITDA$ -1.57M$ -2.17M$ -1.89M$ -3.48M$ -3.44M
Net Income Common Stockholders$ -1.59M$ -2.19M$ -1.70M$ -3.53M$ -3.49M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 1.05M$ 2.38M$ 4.46M$ 1.45M$ 4.57M
Total Assets$ 6.39M$ 8.23M$ 10.66M$ 7.83M$ 11.85M
Total Debt$ 216.00K$ 239.00K$ 262.00K$ 285.00K$ 307.00K
Net Debt$ -837.00K$ -2.14M$ -4.20M$ -1.16M$ -4.26M
Total Liabilities$ 3.36M$ 3.70M$ 4.00M$ 4.74M$ 5.11M
Stockholders Equity$ 3.04M$ 4.53M$ 6.66M$ 3.08M$ 6.74M
Cash Flow-
Free Cash Flow$ -1.36M$ -2.07M$ -2.46M$ -2.78M$ -6.67M
Operating Cash Flow$ -1.36M$ -2.07M$ -2.46M$ -2.78M$ -6.66M
Investing Cash Flow----$ -3.00K
Financing Cash Flow$ -10.18M$ 10.20M$ 5.46M$ -338.00K$ 2.25M
Currency in USD

ReShape Lifesciences Earnings and Revenue History

ReShape Lifesciences Debt to Assets

ReShape Lifesciences Cash Flow

ReShape Lifesciences Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis